KYMR jumps after KT-621 phase I data beats expectations, matching or topping Dupixent on key biomarkers in Th2 diseases.

Eotaxin-3, a highly specific downstream cytokine of the IL-4/IL-13 pathway, was also measured. Eotaxin-3 reduction was observed for all KT-621 dose groups with a median reduction of 63% at Day 14.

and Eotaxin-3 respectively, two signaling molecules that play an active role in recruiting immune cells. Dupilumab, which is taken by more than one million patients, is approved for both eczema ...

Additionally, Eotaxin-3 reduction was more effective than Dupixent. Citi analysts are confident that these findings de-risk KT-621 ahead of its phase 1b atopic dermatitis readout expected in Q4 2025.

I think gives us a lot of confidence in addition to the fact that we could see effects that were either DUPI like or even superior to DUPI on TARC and on Eotaxin three, which is telling us that ...

Morgan Stanley, BofA, and Citi upgraded the stock, citing strong safety, biomarker, and degradation data for its STAT6 degrader KT-621.

Complete STAT6 degradation achieved in both blood and skin at all MAD doses ≥50 mg KT-621 impact on Th2 biomarkers in line or superior to dupilumab with median TARC reduction up to 37% and median ...

Figure 1: Targeted disruption of the mouse C3aR gene. Figure 3: Assessment of AHR to inhaled methacholine (MCh) in conscious mice. We immunized mice with 10 µg of OA and 1 mg of aluminium ...

Bagnasco has received speaker’s honoraria and advisory board membership from AstraZeneca, Chiesi, Firma, GSK, Novartis, Menarini, Sanofi, and Zambon. Berti has received funding from GSK for advisory ...

Nanomaterials in Health Laboratory, Department of Materials Meet Life, Swiss Federal Laboratories for Materials Science and Technology (Empa), St. Gallen 9014, Switzerland ...